Results 51 to 60 of about 20,386 (204)

The resistance of swine blood clots to alteplase-induced thrombolysis in vitro is concentration-dependent

Thrombosis Update, 2021
Background: Swine have been used as a large animal translational research model to investigate the effectiveness of fibrinolytic agents. However, swine thrombi have different characteristics than human thrombi, which may confer more resistance to ...
Evandro M. Neto-Neves, Daren M. Beam, Jeffrey A. Kline   +2 more
doaj   +1 more source

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]

, 2009
<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Cucchiara, B., Demchuk, A., Kasner, S.E., Lees, K.R., Levine, S.R., Lyden, P., Messe, S.R., Sansing, L., Tanne, D.   +8 more
core   +1 more source

Prognostic Factors in Patients With Submacular Haemorrhage Complicating Age‐Related Macular Degeneration: A Post Hoc Analysis of the STAR Study

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To investigate prognostic factors of recent submacular haemorrhage (SMH) complicating neovascular age‐related macular degeneration (nAMD) treated with surgery or pneumatic displacement combined with intravitreal injection of anti‐vascular endothelial growth factor.
Pierre‐Henry Gabrielle, Petra Eid, Ludwig Serge Aho, Laurent Kodjikian, Eric Souied, Joel Uzzan, Jean Baptiste Conart, Marie‐Noëlle Delyfer, Catherine Creuzot‐Garcher   +8 more
wiley   +1 more source

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset

Frontiers in Neurology, 2023
BackgroundStandard-dose intravenous alteplase for acute ischemic stroke (AIS) in the unknown or extended time window beyond 4.5 h after symptom onset is both effective and safe for certain patients who were selected based on multimodal neuroimaging ...
Zekun Wang, Kangxiang Ji, Qi Fang
doaj   +1 more source

Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation [PDF]

, 2010
<p><b>Background and Purpose:</b> Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant, tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early ...
Awadh, M., Baird, T., MacDougall, N., Muir, K.W., Santosh, C., Teasdale, E.   +5 more
core   +1 more source

Iodinated contrast media and cerebral hemorrhage after intravenous thrombolysis [PDF]

, 2011
<p>Background and Purpose: Iodinated contrast is increasingly used in CT perfusion or angiographic examinations in acute stroke. Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been ...
Evelyn Teasdale, Ferghal McVerry, Keith W. Muir, Niall J.J. MacDougall, Sally Baird, Tracey Baird, Wilcox J   +6 more
core   +1 more source

Individualized Treatment in Distal and Medium Vessel Occlusion Stroke Using a Validated Explainable Counterfactual Treatment Estimation Model

Annals of Neurology, Volume 99, Issue 5, Page 1198-1209, May 2026.
Objective The optimal treatment for distal medium vessel occlusion (DMVO) stroke remains uncertain, and evidence comparing endovascular therapy (EVT) with medical management (MM) is limited. We aimed to develop and validate a predictive modeling tool to assess individual treatment benefit in DMVO stroke using explainable counterfactual treatment ...
Mohamed F. Doheim, Mahmoud H. Mohammaden, Hend Abdelhamid, Marta Olive‐Gadea, Marc Rodrigo‐Gisbert, Manuel Requena, Johanna T. Fifi, James E. Siegler, Santiago Ortega‐Gutierrez, Mohamad Abdalkader, Ali Alaraj, Wei Hu, Thanh N. Nguyen, Diogo C. Haussen, Raul G. Nogueira   +14 more
wiley   +1 more source

A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch

Stroke: Vascular and Interventional Neurology
Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, is Food and Drug Administration‐approved for the treatment of acute ischemic stroke and currently the standard of care for thrombolytic therapy.
Miguel Rodriguez, Christian Sidebottom, Drew A. Wells, Thirumalaivasan Dhasakeerthi, Lisa Hayes, Cheran Elangovan, Balaji Krishnaiah   +6 more
doaj   +1 more source

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]

, 2017
Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat, Applegate, Richard, Araujo, Camila, Ho, Wing Mann, Huang, Lei, Reis, Cesar, Zhang, John H   +6 more
core   +3 more sources

Association and Comparative Analysis of Four Inflammatory Indices With 90‐Day Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis

Brain and Behavior, Volume 16, Issue 5, May 2026.
ABSTRACT Objective To investigate and compare the associations of the systemic immune‐inflammation index (SII), the systemic inflammation response index (SIRI), the platelet‐to‐lymphocyte ratio (PLR), and the neutrophil‐to‐lymphocyte ratio (NLR) with 90‐day functional outcomes in AIS patients treated with IV rt‐PA., with particular attention to their ...
Xinping Bai, Xiangyu Wu, Zhuo Cai, Hao Cheng, Juluo Chen   +4 more
wiley   +1 more source